XM Therapeutics

The Extracellular Matrix (ECM) - the scaffolding material that organizes cells into tissues and organs - is a proactive participant in chronic disorders enabling continued inflammation, fibrosis and ischemia. Spun off from Brown University in 2022, XM Therapeutics is developing a platform technology to directly modulate the dysfunctional ECM to improve tissue function and enable organ repair. We generate injectable, acellular designer ECM Particles sourced from human 3D cell cultures. Our initial focus is on cardiovascular and pulmonary indications with significant additional potential in other diseases. We are a Providence, RI - based seed stage start-up with a clear mission: to improve the health status of patients with chronic disorders by modulating and repairing the dysfunctional Extracellular Matrix.